**Suppl Table 2: Adverse events regardless of relationship to the study drug**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Adverse events** | **HKT288 0.3 mg/kg Q3W**  **N=6; n (%)** | | | | **HKT288 0.75 mg/kg Q3W**  **N=3; n (%)** | | | | **All patients**  **N=9; n (%)** |
| **Number of patients with at least one event** | **6 (100.0)** | | | | **2 (66.7)** | | | | **8 (88.9)** |
| **Grade** | **All grades** | **Grade**  **1** | **Grade**  **2** | **Grade**  **3** | **All grades** | **Grade**  **1** | **Grade**  **2** | **Grade**  **3** |  |
| Pyrexia | 4  (66.7) | 3  (50.0) | 1  (16.7) | - | - | - | - | - | 4 (44.4) |
| Constipation | 3  (50.0) | 3  (50.0) | - | - | 1 (33.3) | 1  (33.3) | - | - | 4 (44.4) |
| Fatigue | 3  (50.0) | 1  (16.7) | 2  (33.3) | - | - | - | - | - | 3 (33.3) |
| Vomiting | 2  (33.3) | 2  (33.3) | - | - | 1 (33.3) | 1  (33.3) | - | - | 3 (33.3) |
| Dyspnea | 2  (33.3) | 1  (16.7) | 1  (16.7) | - | - | - | - | - | 2 (22.2) |
| Anemia | 1  (16.7) | - | 1  (16.7) | - | 1 (33.3) | - | 1  (33.3) | - | 2 (22.2) |
| Nausea | 1  (16.7) | 1  (16.7) | - | - | 1 (33.3) | - | 1  (33.3) | - | 2 (22.2) |
| Dysphonia | 1  (16.7) | 1  (16.7) | - | - | 1 (33.3) | 1  (33.3) | - | - | 2 (22.2) |
| Angina pectoris | 1  (16.7) | - | - | 1  (16.7) | - | - | - | - | 1 (11.1) |
| Tachycardia | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Conjunctival hyperemia | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Eye pain | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Abdominal discomfort | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Abdominal pain upper | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Stomatitis | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Chills | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Edema peripheral | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Pain | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Cytokine release syndrome | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Lower respiratory tract infection | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Rhinitis | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Upper respiratory tract infection | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Decreased appetite | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Arthralgia | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Back pain | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Bone pain | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Musculoskeletal stiffness | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Myalgia | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Paget’s disease of nipple | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Neuropathy peripheral | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Partial seizures | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Bronchospasm | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Dyspnea exertional | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Hypoxia | 1  (16.7) | - | 1  (16.7) | - | - | - | - | - | 1 (11.1) |
| Sputum discolored | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Dermatitis acneiform | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Pruritus | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Rash | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Skin discoloration | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Hypertension | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Hypotension | 1  (16.7) | 1  (16.7) | - | - | - | - | - | - | 1 (11.1) |
| Encephalopathy | - | - | - | - | 1 (33.3) | - | 1  (33.3) | - | 1 (11.1) |
| Neuralgia | - | - | - | - | 1 (33.3) | - | 1  (33.3) | - | 1 (11.1) |
| Seizure | - | - | - | - | 1 (33.3) | - | 1  (33.3) | - | 1 (11.1) |
| Aphasia | - | - | - | - | 1 (33.3) | - | 1  (33.3) | - | 1 (11.1) |
| Dry Mouth | - | - | - | - | 1 (33.3) | 1  (33.3) | - | - | 1 (11.1) |
| Pain in Extremity | - | - | - | - | 1 (33.3) | - | - | 1  (33.3) | 1 (11.1) |

**NOTE:** A subject with multiple severity grades for an AE is only counted under the maximum grade.

Q3W, every 3 weeks.